Skip to main content
Premium Trial:

Request an Annual Quote

Waters Said Organic Q1 Revenues Grew 3 Percent; Income Up 14 Percent

NEW YORK, April 26 (GenomeWeb News) - Waters today said that first-quarter revenues increased 5 percent to $268.3 million from $255.1 million year over year.


Waters said that a foreign currency translation benefit accounted for approximately 2 percent of its first-quarter revenue growth, meaning that organic growth amounted to 3 percent.


Waters spent $16.7 million on research and development during the first quarter, a slight increase over the $16.1 million spent on R&D in the same quarter last year.


The company said net income for the three months ended March 31 increased 14 to $46.6 million, or $.39 per basic share, from $40.8 million, or $.34 per basic share, in the year-ago period.


Waters said that cash and cash equivalents on hand totaled $587 million as of April 2.


On March 29, Waters revised its estimate of 2005 sales growth to between 3 and 4 percent from the 13- to 14-percent range it identified in a January conference call with investors. The company also revised its projected first-quarter per-share earnings from $.44 to between $.34 and $.37. In a statement, the firm said that the lowered earnings were the result of "weaker than expected sales growth."

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.